DNA methylation-associated MYBPHL expression in LPS-induced myocardial injury
Septic myocardial injury is a major complication of bacterial infection in children, and effective early biomarkers and therapeutic targets remain insufficiently defined. Studies have shown that Myosin-binding protein H-like (MYBPHL) plays a crucial role in the maintenance of normal cardiac function. This study aimed to explore the association between MYBPHL expression, DNA methylation-related enzymes, and myocardial injury caused by bacterial infection, and to investigate the potential protective role of MYBPHL in an in vitro model. This study combined a clinical cohort with in vitro experiments. (1) Serum samples were collected from 27 children with bacterial infection and 22 age- and sex-matched healthy controls. Levels of LPS, MYBPHL, DNMT1, DNMT3A, BNP, and cTn-I were measured by ELISA. Patient demographics, clinical severity indicators (C-reactive protein, white blood cell count), and septic myocardial injury markers were recorded. (2) Mouse cardiomyocyte (MCM) cells were treated with lipopolysaccharide (LPS, 10 µg/mL, 24 h) to establish an in vitro model of LPS-induced myocardial injury. Expression of DNMT3A, TET1, and MYBPHL was manipulated by overexpression vectors or short hairpin RNA (shRNA) and assessed by RT-qPCR and Western blotting. Cell apoptosis was quantified by flow cytometry (Annexin V-FITC/PI staining) and cTn-I secretion by ELISA. (1) Compared with healthy controls, serum LPS (572.5 ± 41.44 vs. 536.4 ± 55.47 ng/mL), MYBPHL (1445 ± 105.8 vs. 1383 ± 107.1 ng/L), BNP (229.7 ± 19.9 vs. 219.3 ± 12.4 pg/mL), and cTn-I (398.7 ± 27.7 vs. 377.2 ± 33.18 ng/L) were significantly elevated in children with bacterial infection (all P < 0.05), while DNMT3A was significantly decreased (164.7 ± 11.36 vs. 173.8 ± 11.6 pg/mL; P < 0.01); DNMT1 showed no significant difference (915.1 ± 79.14 vs. 917.8 ± 78.16 pg/mL; P = 0.9045). These findings suggest a clinically relevant association between reduced DNMT3A, elevated MYBPHL, and septic myocardial injury. (2) In MCM cells, LPS treatment reduced DNMT3A and DNMT3B expression and increased TET1 expression, changes consistent with a net reduction in DNA methylation, and promoted cardiomyocyte apoptosis ( P < 0.05). Conversely, increasing DNA methylation potential via DNMT3A overexpression or TET1 knockdown suppressed MYBPHL expression and exacerbated LPS-induced myocardial injury. This injury was partially rescued by MYBPHL re-expression. MYBPHL may exert a compensatory, protective response against septic myocardial injury. Its expression is associated with and may be negatively regulated by the DNA methylation machinery, primarily through DNMT3A and TET1. MYBPHL represents a potential candidate biomarker and therapeutic target for septic myocardial injury in children. Future studies employing animal models and genome-wide bisulfite sequencing are warranted to confirm whether direct methylation of the MYBPHL promoter occurs and to extend these findings in vivo.
Authors
- Airong Huang
- 林楚君
- 林苗苗
- Hailun Cai
- YangYang Wu
- Lisha Ge
- Weihao Yu
- Shanhu Wang
- Jingxiang Du
Institutions
- Wenzhou Medical University (CN)
- Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- BMC Medical Genomics
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1186/s12920-026-02495-3
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wenzhou Municipal Science and Technology Bureau